Lacerta Therapeutics Management
Lacerta’s outstanding scientific talent base is complemented by experienced business professionals with demonstrated strengths in biotechnology start-up management, business strategy, finance, technology licensing and laboratory operations.
Joseph Reddy, PhD
President & Chief Executive Officer
Dr. Reddy has over 15 years of progressive leadership in life science research, business management and product development. He has led biotech start-ups in agricultural biotechnology, therapeutics and medical devices, across the R&D-commercial continuum. As an Entrepreneur in Residence at the Florida Institute for Commercialization of Public Research, he has worked with numerous start-up companies as an advisor, provided interim management support and served on their Boards to ensure successful commercialization of technology licensed from public research institutions in Florida. Previously, he was the Director of Program Management at Nanotherapeutics, Inc., where he has managed several multi-million dollar NIH/BARDA grants and contracts. He received his Ph.D. from the University of Idaho and his M.B.A. from the University of Florida.
Edgardo Rodríguez-Lebrón, PhD
Chief Scientific Officer
Dr. Rodríguez-Lebrón has over 18 years of experience in the use of AAV as a CNS gene delivery vector. His research has relied on the use of model systems to test novel gene-based therapies that prevent, halt or reverse neurodegenerative processes caused by the abnormal accumulation of misfolded proteins. He has pioneered AAV-based gene therapies that make use of microRNA molecules and gene editing tools to suppress the expression of these proteins in CNS resident cells. Before joining Lacerta as CSO, Dr. Rodríguez-Lebrón held a faculty appointment in the Department of Pharmacology and Therapeutics at the University of Florida. He received his Ph.D. in Neuroscience from the University of Florida where he trained in the laboratories of Drs. Ron Mandel, Alfred Lewin and Nicholas Muzyczka.